Sangamo Therapeutics (SGMOQ) Net Cash Flow (2010 - 2025)

Sangamo Therapeutics has reported Net Cash Flow for 16 years, with the latest figure at -$9.6 million in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 293.8% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was -$26.6 million, a 2045.48% decrease from a year earlier, with the FY2025 full-year figure at -$26.6 million, down 2045.48% from the prior year.
• Net Cash Flow was -$9.6 million for Q4 2025 at Sangamo Therapeutics, down from -$9.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $46.8 million in Q2 2021, with the low at -$58.8 million in Q1 2022.
• Average Net Cash Flow over 5 years is -$5.8 million, with a median of -$8.7 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow tumbled 633.08% in 2022, then jumped 220.71% in 2024.
• Over 5 years, Net Cash Flow stood at $2.0 million in 2021, then soared by 150.81% to $5.1 million in 2022, then slumped by 348.34% to -$12.7 million in 2023, then surged by 139.2% to $5.0 million in 2024, then sank by 293.8% to -$9.6 million in 2025.
• The last three Net Cash Flow figures came in at -$9.6 million (Q4 2025), -$9.4 million (Q3 2025), and $10.4 million (Q2 2025), per Business Quant data.